Semaglutide or tirzepatide
Intervention1 paper4 findings
In a human trial involving patients with obesity and heart failure with preserved ejection fraction, semaglutide or tirzepatide reduces body weight and heart failure risk, and improves six-minute walk distance and Kansas City Cardiomyopathy Questionnaire clinical summary scores.
Outcomes
3Body weight
downin humans1High certainty
1 study
Body weight
downin humans1High certainty
Semaglutide or tirzepatide decreases body weight in humans (-7.73%, 95% CI -10.70 to -4.76).
Human trialin patients with heart failure with preserved ejection fraction and obesity
The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis · Nutrition, metabolism, and cardiovascular diseases : NMCD · 8 Sep 2026
6-minute walk distance
upin humans1High certainty
1 study
6-minute walk distance
upin humans1High certainty
Semaglutide or tirzepatide improves 6-minute walk distance in humans (+17.18 m, 95% CI 11.82-22.54).
Human trialin patients with heart failure with preserved ejection fraction and obesity
The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis · Nutrition, metabolism, and cardiovascular diseases : NMCD · 8 Sep 2026
Kansas City Cardiomyopathy Questionnaire clinical summary score
upin humans1High certainty
1 study
Kansas City Cardiomyopathy Questionnaire clinical summary score
upin humans1High certainty
Semaglutide or tirzepatide improves Kansas City Cardiomyopathy Questionnaire clinical summary score in humans (+7.39 points, 95% CI 5.43-9.35).
Human trialin patients with heart failure with preserved ejection fraction and obesity
The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis · Nutrition, metabolism, and cardiovascular diseases : NMCD · 8 Sep 2026
Kansas City Cardiomyopathy Questionnaire clinical summary score →
Associations
1Heart failure
downin humans1RR 0.45High certainty
1 study
Heart failure
downin humans1RR 0.45High certainty
Semaglutide or tirzepatide lowers the risk of heart failure in humans (RR 0.45, 95% CI 0.31-0.66).
Human trialin patients with heart failure with preserved ejection fraction and obesity
The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis · Nutrition, metabolism, and cardiovascular diseases : NMCD · 8 Sep 2026